independent.co.ug1d
‘Antiretrovirals Alone Will Not End the HIV Pandemic’
HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...
Bay Area Reporter2d
LGBTQ Agenda: Biden administration expands injectable PrEP coverage
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Bridging the gap between science and community in HIV response
Natal, alarming gaps between scientific advancements and community behaviour persist. This article explores the critical need ...
ABC News25d
Why progress against HIV/AIDS has stalled among Hispanic and Latino Americans
which may result in missed HIV diagnoses or a missed opportunity to receive post-exposure prophylaxis, which can reduce the risk of HIV when taken within 72 hours after a possible HIV exposure.
AllAfrica.com8d
Africa: 'Antiretrovirals Alone Will Not End the HIV Pandemic' - 4 Key Takeaways from #HIVR4P2024
The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...
pharmaphorum7h
Gilead's HIV success and controversy: Expanding access amid criticism
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Part of the GBHSH community in Spain uses doxycycline to prevent sexually transmitted diseases
The increasing incidence of sexually transmitted bacterial infections (STIs) is a major public health problem worldwide.
Pathbreaking HIV drug’s generic version to be made in India
Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...
The Associated Press on MSN22d
Takeaways from AP's report on declining condom use among younger generations
Here are key takeaways. Now, there are many options to prevent HIV and other STIs, including pre-exposure prophylaxis (PrEP) ...
Choices For Women And Girls For HIV Prevention: So Near And Yet So Far
Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...
Business Line22d
Dr. Reddy’s and Hetero join hands with Gilead to broaden access to HIV drug Lenacapavir in low-income countries
Dr. Reddy’s Laboratories and Hetero entered separate pacts with Gilead Sciences to manufacture and distribute Lenacapavir in 120 primarily low- and lower- middle income countries (LMICs) under ...